Comparative analysis of calprotectin and helicobacter pylori in the faces and interleukin-6 in the blood of patients with and without COVID-19 before and after the treatment

Abstract

Aim of the study: To examine the state of the gastrointestinal organs of patients, recovered from Covid-19 using indicators of calprotectin and Helicobacter pylori in feces and interleukin-6 in blood, as well as improvement of the treatment. Materials and methods of the study: In accordance with the aim of the study, 100 patients with gastrointestinal symptoms were observed. 42 of them (42%) were men and 58 (58%) were women. Patients were divided into 2 groups. The first group consisted of patients "relatively recovered" from Covid-19 with no detected immunoglobulin M but with gastrointestinal symptoms (27 men and 33 women; average age 55.06±2.1 years). The second, i.e. control group, consisted of patients, who did not have Covid-19 but had gastrointestinal symptoms (15 men and 25 women; average age 63.4±1.5 years). The levels of calprotectin and H. pylori in feces as well as interleukin-6 in the blood of patients involved in the study were measured.Conclusion. Although positive results were observed after the complex treatment in all groups, in all cases, where patients received rebamipide, changes were more evident. In the group receiving rebamipid a reliable decrease in inflammatory processes in the body of the patients, including the gastrointestinal system was also observed. This was shown by a decrease in calprotectin and H.pylori in their feces and interleukin-6 in their blood.